TABLE 3.
Results of the univariate Cox models analyzing the association between MRONJ and time‐dependent variables and results of the multivariate Cox models analyzing the association between MRONJ and selected variables.
| Hazard ratio (95% confidence interval) | p value at Wald Test | |
|---|---|---|
| Univariate Cox models | ||
| Antiogenetic treatment yes (*) versus no | 2.01 (0.80,5.04) | 0.1369 |
| Dental extraction yes versus no | 30.60 (17.66,53.03) | <0.0001 |
| Other dental treatments yes versus no | 4.18 (2.40, 7.25) | <0.0001 |
| Multivariate Cox model | ||
| Age (years)* | 0.0106 | |
| 56 versus 30 | 3.22 (0.70, 14.82) | |
| 65 versus 30 | 3.01 (0.52, 17.56) | |
| 73 versus 30 | 1.58 (0.30, 8.45) | |
| Previous Bisphosphonate Yes versus no | 2.62 (1.40, 4.88) | 0.0024 |
| Type of Tumor | 0.5024 | |
| Prostate versus breast | 0.83 (0.37, 1.89) | |
| Other versus breast | 0.56 (0.21, 1.53) | |
| Dental treatments before starting Dmab Yes versus no | 1.26 (0.59, 2.68) | 0.5517 |
| Antiangiogenetic treatment yes (***) versus no | 3.11 (0.94, 10.26) | 0.0621 |
| Dental extractions yes versus no | 23.40 (12.98, 47.18) | <0.0001 |
| Dental treatments Yes versus no | 3.67 (1.95, 6.88) | 0.0001 |
| Number Dmab doses | <0.0001 | |
| 6 versus 12 | 1.87 (1.15, 3.06) | |
| 6 versus 24 | 9.11 (4.13, 20.09) | |
Note: (*) Concomitant or follow‐up initiated antiangiogenetic drug assumption. (**) 56, 65, and 73 are, respectively, the first quartile, the median and the third quartiles of the age distribution. (***)Concomitant or follow‐up initiated antiangiogenetic drug assumption.